Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Final Appraisal Recommendation Advice number: 0222 – February 2022

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport[®]) 300 units and 500 units powder for solution for injection

Limited submission by Ipsen Limited

Recommendation of the All Wales Medicines Strategy Group

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport[®]) is recommended as an option for use within NHS Wales for the symptomatic treatment of focal spasticity of upper limbs in paediatric cerebral palsy patients, two years of age or older.

Additional note(s):

• Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2626), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0222:

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport[®]) 300 units and 500 units powder for solution for injection. February 2022



NICE accredited

w.nice.ora.uk/accreditatio

NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at http://www.nice.org.uk/about/what-we-do/accreditation